UNDERSTANDING PATIENTS' KNOWLEDGE, ATTITUDES AND PERCEPTIONS TO HERPES ZOSTER INFECTION AND VACCINATION IN GERMANY: RESULTS FROM A CROSS-SECTIONAL SURVEY

Author(s)

Christian Rauschert, MSc, Dr. rer. biol. hum.1, Ahmed Mohy, PhD2, Johannes J. Hain, Dr. Nat.1, Alexandra Jager, MSc, DPhil3, Stephane Deparis, PhD4, Tommi Tervonen, PhD5.
1GSK, Munich, Germany, 2GSK, Wavre, Belgium, 3Kielo Research, Oxford, United Kingdom, 4Kielo Research, Bordeaux, France, 5Kielo Research, Zug, Switzerland.
OBJECTIVES: Herpes zoster (HZ) presents as a pruritic rash and can cause severe complications, particularly postherpetic neuralgia. In Germany, the recombinant zoster vaccine is recommended for adults aged ≥60 years, in addition to adults ≥18 years at increased HZ risk, following expansion of the recommendation from ≥50 years in November 2025.1 This study aimed to assess German patient knowledge, attitudes and perceptions (KAP) regarding HZ infection and vaccination.
METHODS: A cross-sectional online survey was conducted (August-November 2025) among adults aged ≥60 years from the general population and aged 18-59 years at increased HZ risk. Outcomes included knowledge/attitudes of HZ and vaccination, and perceived importance of information sources, stratified by age (18-49, 50-59 and ≥60 years). Knowledge was assessed using categorical responses, and attitudes/perceptions using Likert-scale and categorical items, including the Adult Vaccine Hesitancy Scale (aVHS; score range: 10-50).
RESULTS: Among 599 respondents, 45% were 18-49, 17% were 50-59, 38% were ≥60 years, and 61% were male. Common comorbidities included diabetes (42%) and rheumatic inflammatory diseases (34%). Prior HZ was reported by ~34% of both at-risk 18-49 and 50-59 years age groups, and ~19% of adults ≥60 years. Overall, HZ awareness was high (83%), but fewer recognised HZ recurrence (58%) or understood how HZ is developed (57%). Perceived vaccination importance increased with age; 58% of 18-49, 60% of 50-59, and 70% of ≥60 years considered vaccination “very important”, alongside proactive vaccine enquiry to a healthcare professional (HCP; 43%/48%/58%). One-third of patients were vaccine-hesitant (aVHS ≥25), decreasing with age (40%/33%/23%). HCPs were most frequently rated as “very important” vaccination information sources (64%/57%/66%), compared with family (44%/52%/36%) and social media (24%/24%/20%).
CONCLUSIONS: These findings highlight gaps in patient KAP regarding HZ infection and vaccination, which could be addressed by improved patient communication.
1STIKO Recommendations. https://www.rki.de/EN/Topics/Infectious-diseases/Immunisation/STIKO/STIKO-recommendations/Downloads/04_26_english.pdf?__blob=publicationFile&v=4
Funding: GSK (GSK study identifier: 224324)

Conference/Value in Health Info

2026-11, ISPOR Europe 2026, Vienna, Austria

Value in Health, Volume 29, Issue 12S

Code

EPH100

Topic

Epidemiology & Public Health, Patient-Centered Research, Study Approaches

Topic Subcategory

Public Health

Disease

Infectious Disease (non-vaccine), Vaccines

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×